APOLLOMICS INC-27 (APLMW) Stock News

USA - NASDAQ:APLMW -

0.0191 USD

+0 (+14.37%)

Last: 9/17/2025, 8:23:31 PM

Technical Analysis

APLMW Latest News, Press Relases and Analysis

All

Press Releases

6 months ago - By: Apollomics Inc. - Mentions: APLM

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

6 months ago - By: Apollomics Inc. - Mentions: APLM

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

7 months ago - By: Apollomics Inc. - Mentions: APLM

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

7 months ago - By: Apollomics Inc. - Mentions: APLM

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

10 months ago - By: Apollomics Inc. - Mentions: APLM

Apollomics 公布 Uproleselan 在中國治療復發或難治性急性髓系白血病患者的第 3 期銜接性試驗的主要結果

10 months ago - By: Apollomics Inc. - Mentions: APLM

Apollomics 公布在中国对复发或难治性急性髓系白血病患者进行的 Uproleselan III 期桥接试验主要结果

10 months ago - By: Apollomics Inc. - Mentions: APLM

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

10 months ago - By: Apollomics Inc. - Mentions: APLM

Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

10 months ago - By: Apollomics Inc. - Mentions: APLM

Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

a year ago - By: Apollomics Inc. - Mentions: APLM

Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split

a year ago - By: Apollomics Inc. - Mentions: APLM

Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split

a year ago - By: Apollomics Inc. - Mentions: APLM

Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024

a year ago - By: Apollomics Inc. - Mentions: APLM

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

a year ago - By: Apollomics Inc. - Mentions: APLM

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

a year ago - By: Apollomics Inc. - Mentions: APLM

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

a year ago - By: Apollomics Inc. - Mentions: APLM

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

a year ago - By: Apollomics Inc. - Mentions: APLM

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

a year ago - By: Apollomics Inc. - Mentions: APLM

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

a year ago - By: Apollomics Inc. - Mentions: APLM

Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference

a year ago - By: Apollomics Inc. - Mentions: APLM

Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference

a year ago - By: Apollomics Inc. - Mentions: APLM

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement